FDA Approved: NULIBRY — Supplemental Application (Sentynl Therapeutics, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for NULIBRY (fosdenopterin hydrobromide) from Sentynl Therapeutics, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Molybdenum Cofactor Deficiency Type

Drugs mentioned

• Nulibry (fosdenopterin)

Snippet

SUPPL AP for NULIBRY (FOSDENOPTERIN HYDROBROMIDE)